Scarica l'app Stockscreener
3.65
3.99%
0.14
Dopo l'orario di chiusura:
3.65
Precedente Chiudi:
$3.51
Aprire:
$3.51
Volume 24 ore:
1.39M
Relative Volume:
1.28
Capitalizzazione di mercato:
$312.77M
Reddito:
$380.79M
Utile/perdita netta:
$49.27M
Rapporto P/E:
5.2143
EPS:
0.7
Flusso di cassa netto:
$10.68M
1 W Prestazione:
+1.39%
1M Prestazione:
-3.44%
6M Prestazione:
+77.18%
1 anno Prestazione:
-77.19%
Intervallo 1D:
$3.47
$3.75
Intervallo di 1 settimana:
$3.2109
$3.75
Portata 52W:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Industria
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Confronta AMLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.65 | 312.77M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2023-01-05 | Iniziato | BofA Securities | Buy |
| 2022-05-25 | Iniziato | Citigroup | Buy |
| 2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
FY2025 Earnings Forecast for AMLX Issued By Leerink Partnrs - MarketBeat
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
JPMorgan Chase & Co. Purchases 83,048 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - Markets Insider
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
FDA lifts clinical hold on Amylyx ALS drug study - MSN
FDA clears Amylyx to resume ALS drug trial in North America - MSN
Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020 - Marketscreener.com
Clinical hold lifted from Phase 1 trial of ALS therapy AMX0114 - ALS News Today
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets - BioSpace
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial - MarketWatch
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - MarketBeat
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - AccessWire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - AccessWire
Amylyx Pharmaceuticals Prices of Public Offering of Common Stock - citybiz
Amylyx stock dips after pricing $60M stock offering - MSN
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Announces Common Stock Offering to Fuel Commercialization Plans - StockTitan
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
Amylyx Pharmaceuticals co-CEO Justin Klee sells $30,201 in stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - AccessWire
Justin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock - MarketBeat
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 - Investing.com
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - AccessWire
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer - citybiz
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
AMYLYX PHARMACEUTICALS 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Amylyx - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - AccessWire
Amylyx and Gubra collaborate to develop long-acting GLP-1 receptor antagonist - BioWorld Online
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 8.3% in December - MarketBeat
Amylyx inks deal with Gubra for diabetes treatment By Investing.com - Investing.com Nigeria
Amylyx inks deal with Gubra for diabetes treatment - Investing.com India
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
Gubra A/S Announces New Collaboration with Amylyx Pharmaceuticals, Inc. to Develop a Novel Long-Acting GLP-1 Receptor Antagonist - Marketscreener.com
Amylyx Partners with Gubra for GLP-1 Antagonist - TipRanks
Gubra in collaboration with Amylyx to develop long-acting GLP-1 antagonists - Marketscreener.com
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):